PDGFRA alterations in cancer: Characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations

Oncogene

Volumn 33, Issue 20, 2014, Pages 2568-2576

  Velghe, A I ^a   Van Cauwenberghe, S ^a   Polyansky, A A ^b,c   Chand, D ^d   Montano Almendras, C P ^a   Charni, S ^a   Hallberg, B ^d   Essaghir, A ^a   Demoulin, J B ^a  

^a DE DUVE INSTITUTE   (Belgium)

^b UNIVERSITY OF VIENNA   (Austria)

^c SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

GIST; glioblastoma; leukemia; PDGF receptor; tyrosine kinase inhibitors

Indexed keywords

DIMER; IMATINIB; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STAT5 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALGORITHM; ANIMAL CELL; ARTICLE; CELL GROWTH; CELL MIGRATION; CELL STIMULATION; CELL SURFACE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MELANOMA; MUTANT; NEOPLASM; NEUROENDOCRINE TUMOR; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

AMINO ACID SEQUENCE; FLOW CYTOMETRY; GLYCOSYLATION; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; POINT MUTATION; PROTEIN TRANSPORT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84901199522     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.218     Document Type: Article

References (44)

1. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276-1312. (Pubitemid 351717519
2. Chiara F, Bishayee S, Heldin CH, Demoulin JB. Autoinhibition of the plateletderived growth factor beta-receptor tyrosine kinase by its C-Terminal tail. J Biol Chem 2004; 279: 19732-19738. (Pubitemid 38623411
3. Toffalini F, Demoulin JB. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 2010; 116: 2429-2437
4. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P et al. PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357-5364. (Pubitemid 46206989
5. Demoulin JB, Montano-Almendras CP. Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. Am J Blood Res 2012; 2: 44-56
6. Medves S, Demoulin JB. Tyrosine kinase gene fusions in cancer: Translating mechanisms into targeted therapies. J Cell Mol Med 2012; 16: 237-248
7. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214. (Pubitemid 36359296
8. Elling C, Erben P, Walz C, Frickenhaus M, Schemionek M, Stehling M et al. Novel imatinib-sensitive PDGFRA-Activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011; 117: 2935-2943
9. Huss S, Wardelmann E, Goltz D, Binot E, Hartmann W, Merkelbach-Bruse S et al. Activating PDGFRA mutations in inflammatory fibroid polyps occur in exons 12, 14 and 18 and are associated with tumour localization. Histopathology 2012; 61: 59-68
10. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110
11. Clarke ID, Dirks PB. A human brain tumor-derived PDGFR-Alpha deletion mutant is transforming. Oncogene 2003; 22: 722-733. (Pubitemid 36269285
12. Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-Amplified glioblastomas. Genes Dev 2010; 24: 2205-2218
13. David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABLnegative chronic myeloproliferative disorders. Blood 2007; 109: 61-64. (Pubitemid 46053044
14. Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: A phase-II study. Br J Haematol 2008; 143: 707-715
15. Paulsson J, Lindh MB, Jarvius M, Puputti M, Nister M, Nupponen NN et al. Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Int J Cancer 2011; 128: 1981-1988
16. Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol 2010; 96: 393-402
17. Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, Atallah I et al. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis 2006; 27: 664-671. (Pubitemid 43372895
18. Hiwatari M, Taki T, Tsuchida M, Hanada R, Hongo T, Sako M et al. Novel missense mutations in the tyrosine kinase domain of the platelet-derived growth factor receptor alpha(PDGFRA) gene in childhood acute myeloid leukemia with t(8;21)(q22;q22) or inv(16)(p13q22). Leukemia 2005; 19: 476-477
19. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-158. (Pubitemid 46398669
20. Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci USA 2005; 102: 14344-14349. (Pubitemid 41429700
21. Alentorn A, Marie Y, Carpentier C, Boisselier B, Giry M, Labussiere M et al. Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in Diffuse gliomas. Neuro Oncol 2012; 14: 1393-1403
22. Toffalini F, Hellberg C, Demoulin JB. Critical role of the platelet-derived growth factor receptor (PDGFR)-beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein. J Biol Chem 2010; 285: 12268-12278
23. Keating MT, Harryman CC, Williams LT. Platelet-derived growth factor receptor inducibility is acquired immediately after translation and does not require glycosylation. J Biol Chem 1989; 264: 9129-9132. (Pubitemid 19157541
24. Burke CL, Lemmon MA, Coren BA, Engelman DM, Stern DF. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation. Oncogene 1997; 14: 687-696. (Pubitemid 27095860
25. Yang Y, Yuzawa S, Schlessinger J. Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization. Proc Natl Acad Sci USA 2008; 105: 7681-7686. (Pubitemid 351872698
26. Polyansky AA, Volynsky PE, Efremov RG. Multistate organization of transmembrane helical protein Dimers governed by the host membrane. J Am Chem Soc 2012; 134: 14390-14400
27. Muhle-Goll C, Hoffmann S, Afonin S, Grage SL, Polyansky AA, Windisch D et al. Hydrophobic matching controls the tilt and stability of the dimeric plateletderived growth factor receptor (PDGFR) beta transmembrane segment. J Biol Chem 2012; 287: 26178-26186
28. Bell CA, Tynan JA, Hart KC, Meyer AN, Robertson SC, Donoghue DJ. Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase. Mol Biol Cell 2000; 11: 3589-3599
29. Arkhipov A, Shan Y, Das R, Endres NF, Eastwood MP, Wemmer DE et al. Architecture and membrane interactions of the EGF receptor. Cell 2013; 152: 557-569
30. Endres NF, Das R, Smith AW, Arkhipov A, Kovacs E, Huang Y et al. Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 2013; 152: 543-556
31. Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, Schlessinger J. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 2007; 130: 323-334. (Pubitemid 47081138
32. Omura T, Heldin CH, Ostman A. Immunoglobulin-like domain 4-mediated receptor-receptor interactions contribute to platelet-derived growth factorinduced receptor dimerization. J Biol Chem 1997; 272: 12676-12682. (Pubitemid 27203365
33. Schonherr C, Ruuth K, Eriksson T, Yamazaki Y, Ottmann C, Combaret V et al. The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro and in vivo. Transl Oncol 2011; 4: 258-265
34. Demoulin JB, Seo JK, Ekman S, Grapengiesser E, Hellman U, Ronnstrand L et al. Ligand-induced recruitment of Na/H-exchanger regulatory factor to the PDGF (platelet-derived growth factor) receptor regulates actin cytoskeleton reorganization by PDGF. Biochem J 2003; 376: 505-510. (Pubitemid 38010536
35. Takahashi Y, Morales FC, Kreimann EL, Georgescu MM. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J 2006; 25: 910-920. (Pubitemid 43292451
36. Frohling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA et al. Identification of driver and passenger mutations of FLT3 by high-Throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007; 12: 501-513. (Pubitemid 350199072
37. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: Server and survey. Nucleic Acids Res 2002; 30: 3894-3900. (Pubitemid 35012462
38. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2013; 110: 1398-1403
39. Toffalini F, Kallin A, Vandenberghe P, Pierre P, Michaux L, Cools J et al. The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation. Haematologica 2009; 94: 1085-1093
40. Demoulin JB, Uyttenhove C, Van Roost E, de Lestre B, Donckers D, Van Snick J et al. A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9. Mol Cell Biol 1996; 16: 4710-4716. (Pubitemid 26272124
41. Montano-Almendras CP, Essaghir A, Schoemans H, Varis I, Noel LA, Velghe AI et al. ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor proliferation and differentiation into eosinophils: Role of NF-kappaB. Haematologica 2012; 97: 1064-1072
42. Demoulin JB, Ericsson J, Kallin A, Rorsman C, Ronnstrand L, Heldin CH. Plateletderived growth factor stimulates membrane lipid synthesis through activation of phosphatidylinositol 3-kinase and sterol regulatory element-binding proteins. J Biol Chem 2004; 279: 35392-35402
43. Schonherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, Combaret V et al. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene 2012; 31: 5193-5200
44. Medves S, Noel LA, Montano-Almendras CP, Albu RI, Schoemans H, Constantinescu SN et al. Multiple oligomerization Domains of KANK1-PDGFRB are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK. Haematologica 2011; 96: 1406-1414